Literature DB >> 6980824

Murine B-lymphocyte colony formation: the effects of cyclophosphamide and azathioprine.

A Winkelstein.   

Abstract

The present studies assessed the relationship between murine splenic B-lymphocyte colony-forming cells and the number of mature B lymphocytes in the spleen following administration of either cyclophosphamide or azathioprine. Cyclophosphamide (200 mg/kg) reduced the number of splenic B lymphocytes by a mean of 77%. However, a greater reduction in colony-forming cells was noted. Five days after cyclophosphamide administration, the number of colonies per spleen was reduced by more than 90%. Furthermore, the recovery of colony-forming activity was delayed in comparison with restoration of the B-cell system. The number of B lymphocytes returned to normal by day 10; colony formation was still reduced on day 28. Azathioprine, administered for 5 consecutive days, caused only a minimal reduction in B-cell clonal growth. These findings suggest that colony-forming cells may not be progenitor cells which are required for recovery from drug-induced lymphocyte destruction. Rather, this activity may be a property of mature B cells. The majority of potential colony-forming cells appear to be non-proliferating, as the phase-specific drug azathioprine caused only minimal reduction in colony-forming activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6980824      PMCID: PMC1555482     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  17 in total

1.  Growth of B lymphocyte colonies in vitro from mouse lymphoid organs.

Authors:  D Metcalf; N L Warner; G J Nossal; J F Miller; K Shortman; E Rabellino
Journal:  Nature       Date:  1975-06-19       Impact factor: 49.962

Review 2.  Elicitation of selective T and B lymphocyte responses by cell surface binding ligands.

Authors:  M Greaves; G Janossy
Journal:  Transplant Rev       Date:  1972

3.  Differential effects of cyclophosphamide on the B and T cell compartments of adult mice.

Authors:  G D Stockman; L R Heim; M A South; J J Trentin
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

4.  Colony growth in vitro of mitogen-stimulated mouse B lymphocytes.

Authors:  L A Rozenszajn; H Michlin; Y Kalechman; B Sredni
Journal:  Immunology       Date:  1977-03       Impact factor: 7.397

5.  Role of mercaptoethanol and endotoxin in stimulating B lymphocyte colony formation in vitro.

Authors:  D Metcalf
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

6.  Development of B-lymphocyte colony-forming cells in foetal mouse tissues.

Authors:  G R Johnson; D Metcalf; J W Wilson
Journal:  Immunology       Date:  1976-06       Impact factor: 7.397

7.  B lymphocyte colony-forming cells in the SJL/J mouse.

Authors:  M H Claesson; D Metcalf
Journal:  J Immunol       Date:  1977-04       Impact factor: 5.422

8.  Growth of B-lymphocyte colonies in vitro.

Authors:  D Metcalf; G J Nossal; N L Warner; J F Miller; T E Mandel; J E Layton; G A Gutman
Journal:  J Exp Med       Date:  1975-12-01       Impact factor: 14.307

9.  Growth of B-lymphocytes clones in semisolid culture is mitogen dependent.

Authors:  P W Kincade; P Ralph; M A Moore
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

10.  Features of systemic lupus erythematosus in mice injected with bacterial lipopolysaccharides: identificantion of circulating DNA and renal localization of DNA-anti-DNA complexes.

Authors:  S Izui; P H Lambert; G J Fournié; H Türler; P A Miescher
Journal:  J Exp Med       Date:  1977-05-01       Impact factor: 14.307

View more
  2 in total

1.  Cyclophosphamide treatment antagonizes the in vitro development of Mycobacterium lepraemurium-induced suppressor cell precursors.

Authors:  D Gosselin; R Turcotte; S Lemieux
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

2.  Resistance of human T-CFUcs to activated cyclophosphamide: a feature common with critical marrow stem cells?

Authors:  J E Byfield; P M Calabro-Jones
Journal:  Br J Cancer       Date:  1985-09       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.